Genus Rating Reiterated by N+1 Singer (GNS)
Genus (LON:GNS)‘s stock had its “hold” rating reaffirmed by equities research analysts at N+1 Singer in a research note issued to investors on Monday, Analyst Ratings Network reports. They currently have a GBX 1,348 ($21.59) target price on the stock. N+1 Singer’s price objective indicates a potential downside of 2.95% from the stock’s previous close.
Shares of Genus (LON:GNS) traded up 1.39% during mid-day trading on Monday, hitting GBX 1389.00. 28,434 shares of the company’s stock traded hands. Genus has a 1-year low of GBX 1270.5601 and a 1-year high of GBX 1609.00. The stock’s 50-day moving average is GBX 1396. and its 200-day moving average is GBX 1416.. The company’s market cap is £840.2 million.
GNS has been the subject of a number of other recent research reports. Analysts at Liberum Capital reiterated a “buy” rating on shares of Genus (LON:GNS) in a research note to investors on Thursday, September 5th. They now have a GBX 1,550 ($24.83) price target on the stock. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Genus (LON:GNS) in a research note to investors on Tuesday, September 3rd. They now have a GBX 1,740 ($27.87) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genus (LON:GNS) in a research note to investors on Tuesday, July 16th. They now have a GBX 949 ($15.20) price target on the stock.
Two analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of GBX 1,364.17 ($21.85).
Genus plc is a United Kingdom-based company. The Company is engaged in applying quantitative genetics and biotechnology to animal breeding in the bovine and porcine sectors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.